scholarly journals Qualitative GC-MS Assessment of TCP and Tamorf Elimination in Rats

2010 ◽  
Vol 61 (1) ◽  
pp. 61-67
Author(s):  
Maja Petek ◽  
Ana Vrdoljak ◽  
Gordan Mršić
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Protective Effect ◽  
Standard Treatment ◽  
Adamantane Derivative ◽  
Cholinergic Receptors ◽  
Rat Urine ◽  
Combined Administration ◽  
The Central Nervous System ◽  
New Compounds

Qualitative GC-MS Assessment of TCP and Tamorf Elimination in RatsNerve agents are highly toxic organophosphorus (OP) compounds. They inhibit acetylcholinesterase (AChE), an enzyme that hydrolyses acetycholine (ACh) in the nervous system. Pathophysiological changes caused by OP poisonings are primarily the consequence of surplus ACh on cholinergic receptors and in the central nervous system. Standard treatment of OP poisoning includes combined administration of carbamates, atropine, oximes and anticonvulsants. In order to improve therapy, new compounds have been synthesised and tested. Tenocyclidine (TCP) and its adamantane derivative 1-[2-(2-thienyl)-2-adamantyl] morpholine (TAMORF) have shown interesting properties against soman poisoning. In this study, we developed a qualitative GC-MS method to measure elimination of TCP and TAMORF through rat urine in order to learn more about the mechanisms through which TCP protects an organism from OP poisoning and to determine the duration of this protective effect. GC-MS showed that six hours after treatment with TCP, rat urine contained only its metabolite 1-thienylcyclohexene, while urine of rats treated with TAMORF contained both TAMORF and its metabolites.

RADT-24. SYNTHETIC TREATMENT OF CENTRAL NERVOUS SYSTEM EWING/PRIMITIVE NEUROECTODERMAL TUMOR (EWING/PNET): A CASE REPORT

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi46-vi46
Author(s):  
yanying Yang ◽  
Changguo Shan ◽  
Weiping Hong ◽  
Linbo Cai
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Standard Treatment ◽  
Whole Brain Radiotherapy ◽  
Good Survival ◽  
Tumor Bed ◽  
Brain Radiotherapy ◽  
Anterior Cranial Base ◽  
Second Resection ◽  
The Central Nervous System

Abstract Ewing/PNET is a rare tumor of the central nervous system. After the standard treatment, there’re still 86.7% of patients had recurrence and no standard treatment after recurrence. Here we report a case of Ewing/PNET with a good survival after synthetic treatment to provide evidence for future clinical strategies. A 23-year-old male underwent resection of the left frontal tumor on April 28, 2017, the pathological diagnosis was Ewing/PNET. He received whole brain radiotherapy 36Gy in 18 fractions, and tumor bed boost to 56Gy in 28 fractions, with 3 courses of Nedaplatin adjuvant chemotherapy. The tumor recured 23 months after the surgery. The patient underwent the second resection, followed by 4 courses of ADM+VCR+CTX/IE chemotherapy. However, 27 months after the first surgery, the tumor evaluation progressive resection of recurrent tumors in the anterior cranial base-ethmoid sinus. During the chemotherapy, MRI showed that tumor still increased. There was a mass in the root of the forehead and nose. After the third recurrence, the patient received re-radiotherapy (50Gy in 25 fractions) 29 months later after the first RT. The tumor was significantly reduced after radiotherapy. Physical examination showed that the sense of smell continued to weaken, the visual acuity was the same as before. 8 courses of VIT (Irinotecan, vincristine, temozolomide) were followed by second RT, tumor was assessed every 2 courses. 44 months after the first surgery, he suffered a third recurrence in spina cord. And then he received rescue RT (20Gy in 10 fractions) in the recurrent tumor. The tumor was reduced after local radiotherapy. He was undergoing follow-up till May 2021, And the OS is 49 months. In conclusion, the incidence of this disease is low, especially in adults. However, the prognosis is poor. Early detection, early operation, combined with radiotherapy and chemotherapy are promising to improve the efficacy of Ewing/PNET.

Involvement of the central nervous system in the protective effect of melanocortins in myocardial ischaemia/reperfusion injury

Resuscitation ◽  
2002 ◽  
Vol 52 (1) ◽  
pp. 109-115 ◽  
Author(s):  
Carla Bazzani ◽  
Chiara Mioni ◽  
Giuseppe Ferrazza ◽  
Maria Michela Cainazzo ◽  
Alfio Bertolini ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Protective Effect ◽  
Reperfusion Injury ◽  
Myocardial Ischaemia ◽  
Ischaemia Reperfusion Injury ◽  
Ischaemia Reperfusion ◽  
The Central Nervous System

scholarly journals Neurocysticercosis presenting as pseudobulbar palsy

2014 ◽  
Vol 5 (01) ◽  
pp. 76-77 ◽  
Author(s):  
Arinaganahalli Subbanna Praveen Kumar ◽  
Dharanitragada Krishna Suri Subrahmanyam
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Standard Treatment ◽  
Cerebral Hemispheres ◽  
Pseudobulbar Palsy ◽  
Partial Seizures ◽  
Mri Brain ◽  
The Central Nervous System ◽  
The Common ◽  
Acquired Epilepsy

ABSTRACTNeurocysticercosis (NCC) is the most common helminthic infestation of the central nervous system (CNS) and a leading cause of acquired epilepsy worldwide. The common manifestations of NCC are seizures and headache. The NCC as a cause of pseudobulbar palsy is very unusual and not reported yet in the literature. A pseudobulbar palsy can occur in any disorder that causes bilateral corticobulbar disease. The common etiologies of pseudobulbar palsy are vascular, demyelinative, or motor neuron disease. We report a 38-year-old female patient who presented with partial seizures and pseudobulbar palsy. The MRI brain showed multiple small cysts with scolex in both the cerebral hemispheres and a giant intraparenchymal cyst. Our patient responded well to standard treatment of neurocysticercosis and antiepileptics.

Sign in / Sign up

Export Citation Format

Share Document